1. Home
  2. IMVT vs TECH Comparison

IMVT vs TECH Comparison

Compare IMVT & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$38.87

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

HOLD

Current Price

$70.83

Market Cap

9.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMVT
TECH
Founded
2018
1976
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
9.1B
IPO Year
2019
1995

Fundamental Metrics

Financial Performance
Metric
IMVT
TECH
Price
$38.87
$70.83
Analyst Decision
Buy
Strong Buy
Analyst Count
8
11
Target Price
$33.00
$71.82
AVG Volume (30 Days)
1.5M
7.4M
Earning Date
05-28-2026
05-06-2026
Dividend Yield
N/A
0.62%
EPS Growth
N/A
N/A
EPS
N/A
0.81
Revenue
N/A
$1,219,635,000.00
Revenue This Year
N/A
$2.49
Revenue Next Year
N/A
$6.40
P/E Ratio
N/A
$87.44
Revenue Growth
N/A
5.23
52 Week Low
$14.32
$43.20
52 Week High
$39.28
$72.16

Technical Indicators

Market Signals
Indicator
IMVT
TECH
Relative Strength Index (RSI) 70.64 77.05
Support Level $25.13 $57.46
Resistance Level N/A $71.10
Average True Range (ATR) 1.32 1.48
MACD 0.12 1.24
Stochastic Oscillator 94.94 97.69

Price Performance

Historical Comparison
IMVT
TECH

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Share on Social Networks: